[Skip to Content]
[Skip to Content Landing]
Article
April 14, 1956

FATAL APLASTIC ANEMIA AFTER THERAPY WITH NUVARONE (3-METHYL-5-PHENYLHYDANTOIN)

JAMA. 1956;160(15):1311-1312. doi:10.1001/jama.1956.02960500041011a
Abstract

The occurrence of blood dyscrasias resulting from therapy with antiepileptic drugs has been emphasized repeatedly in excellent reviews of the literature. Of the well-established hydantoin derivatives, Mesantoin (3-methyl-5,5-phenylethylhydantoin) has been the chief offender in the production of cytopenia. Diphenylhydantoin (Dilantin) sodium has been notably free from hematopoietic toxic reaction.

In the constant search for safer and more effective anticonvulsants, Nuvarone (3-methyl-5-phenylhydantoin) was first studied by Everett and Richards. It was judged safe as a result of animal experiments and early clinical trials. Livingston and Sweet then reported clinical results in 42 patients with no hematological changes found. In Peterman's report on 42 patients, mild leukopenia was observed in 2, with no change in hemoglobin level, red blood cell count, or platelets. The largest study reported has been from the seizure research clinic of Bellevue Psychiatric Hospital by Taterka and Thompson on 91 patients, 25 treated by Nuvarone therapy alone and

×